DaVita (DVA) Stock Price
DaVita Price
Over the last 19 years DaVita grew revenue by 5.6% annually, reaching 13.64 B USD. Earnings per share have grown at 10.0% per year over the last 19 years. For DaVita, the net margin of 5.5% is down versus 8.4% a few years ago. The consensus 12-month price target for DaVita is 222.00 USD, about 23.9% above where the stock trades today. Of 13 analysts, 7 rate the stock a buy — an overall Buy consensus.
DaVita stock price
DaVita business model & stock analysis
Frequently asked questions about DaVita
The main competitors of DaVita Inc in the market include companies like Fresenius Medical Care Holdings, Inc. and American Renal Associates Holdings, Inc.
DaVita Inc is a leading provider of kidney care services in the United States, offering dialysis treatments and related healthcare services. The company operates a network of outpatient dialysis centers and provides specialized medical care to patients suffering from chronic kidney failure. DaVita's business model revolves around delivering high-quality care with a patient-centric focus. By leveraging their extensive network, technological advancements, and skilled healthcare professionals, DaVita aims to improve patients' quality of life and outcomes. With a strong emphasis on innovation, collaboration, and education, DaVita Inc strives to optimize the overall healthcare experience for individuals with kidney-related conditions.
DaVita Inc is primarily active in the healthcare industry.
DaVita Inc is a leading healthcare provider that specializes in kidney care services. Established in 1999, the company has a strong history of delivering high-quality care to patients across the United States and internationally. DaVita is renowned for its innovative approaches to dialysis treatment and comprehensive disease management. The company operates a vast network of outpatient dialysis centers, partnering with physicians in providing integrated care to individuals with chronic kidney disease. With a commitment to improving patients' quality of life, DaVita remains dedicated to the compassionate delivery of kidney care services. DaVita Inc has continually expanded its footprint and leadership in the industry, making it a trusted name in renal care.
DaVita Inc. has achieved several significant milestones throughout its history. The company has expanded its presence globally, becoming one of the largest providers of kidney care services worldwide. DaVita has consistently demonstrated strong financial performance and steady growth, positioning itself as a leader in the industry. It has also received numerous accolades, including being recognized as one of Fortune's World's Most Admired Companies. DaVita Inc. continues to innovate in the field of healthcare, focusing on delivering high-quality patient care and improving outcomes.
DaVita Inc is primarily present in the United States.
DaVita Inc represents a set of core values and a strong corporate philosophy. The company focuses on delivering quality patient care, guided by their motto: "One for All and All for One." DaVita strives to provide exceptional healthcare services with integrity, teamwork, and continuous improvement. Their commitment to clinical excellence and compassion is evident in their Village concept, where employees are called "teammates" and patients are part of the DaVita community. DaVita promotes a culture of caring, innovation, and accountability, ensuring the highest standards of care for their patients.
Analysts currently set an average price target of 235.67 USD for the DaVita stock (median: 222.00 USD), implying +31.5 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the DaVita stock: 7 recommend buying, 5 holding and 1 selling. For 2026, analysts expect DaVita to generate revenue of 14.10 B USD and earnings per share of 12.77 USD.
Converted at the current exchange rate, the DaVita share trades at 159.92 EUR (179.16 USD).
The DaVita share (DVA) is listed on 7 stock exchanges, including: NYSE (DVA), London (0I7E.L), SIX (Zürich) (TRL.SW), Frankfurt (TRL.F), München (TRL.MU), Düsseldorf (TRL.DU).
The business model of DaVita Inc is focused on the healthcare and medical services sector. The company's main focus is on treating patients with chronic kidney diseases. DaVita has developed a comprehensive integrated healthcare solution that includes multiple services. These include renal replacement therapy, care, education, and medical treatment. In recent years, the company has also added expanded services such as nutritional counseling, mental health, and rehabilitation to its portfolio. To provide the necessary medical care and healthcare services, DaVita operates around 2,700 dialysis centers with over 200,000 facilities worldwide. The company also employs over 70,000 staff, including physicians, nursing staff, therapists, and administrative personnel. DaVita offers a wide range of products and services, including hemodialysis, peritoneal dialysis, and home patient equipment. The company also offers various programs to improve patient care quality and increase patient engagement. These programs include global quality and safety initiatives, patient surveys, and electronic medical records. DaVita has also established its own health insurance called DaVita Health Plan, which offers a wide range of health plans in the United States. The company also operates a comprehensive marketing program to raise awareness of its services among patients and physicians. To drive growth in different markets, DaVita seeks to offer the best possible healthcare services through strategic acquisitions and joint ventures. In recent years, the company has announced several acquisitions and partnerships to expand its geographic reach and service offerings. In recent years, the company has been following a trend towards digital innovations. DaVita has transitioned its originally paper-based processes to digital platforms to improve care quality, patient experience, and efficiency. The company also utilizes the latest technologies to offer innovative and personalized services to its patients and improve patient experiences. In summary, DaVita Inc is a leading company in the field of kidney diseases and offers a wide range of healthcare services and products. The company has a strong presence in the United States and operates in various geographical regions worldwide. DaVita has evolved its services over the years and developed an extensive portfolio of products and services, including health insurance, digital platforms, and innovative therapies.
The expected revenue of DaVita is 14.10 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of DaVita is 1.13 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of DaVita is currently 14.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the DaVita stock.
The price-to-sales ratio (P/S) of DaVita is currently 1.12. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the DaVita stock.
The Eulerpool Quality Score for DaVita is 6/10.
The ISIN of DaVita is US23918K1088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of DaVita is 897914. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of DaVita is DVA. The ticker symbol is used to trade DaVita shares on the stock exchange.
DaVita stock
DaVita Peer Group
DaVita Ticker
DaVita FIGI
All fundamentals and in-depth analysis of DaVita
Our stock analysis for DaVita stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DaVita. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.